Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07711171
PHASE4

Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment

Sponsor: Fudan University

View on ClinicalTrials.gov

Summary

The prevalence of cognitive dysfunction in diabetic patients is high, which seriously affects the quality of life of patients, and early intervention is of great significance. Central nervous system insulin resistance plays a key role in the pathogenesis of cognitive dysfunction in diabetic patients. Central insulin resistance observed by functional magnetic resonance imaging (fMRI), may serve as an alternative endpoint for assessing cognitive function. Sodium glucose cotransporter 2 inhibitor (SGLT2i) may improve cognitive impairment by improving central insulin resistance.

Official title: Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment- a Prospective, Randomized, Single-blind, Controlled, Single-center, Head-to-head Clinical Cohort Study

Key Details

Gender

All

Age Range

40 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-08-19

Completion Date

2026-10-30

Last Updated

2026-07-17

Healthy Volunteers

No

Interventions

DRUG

Canagliflozin group

Canagliflozin,100mg once daily, orally, for 6 months

DRUG

Sitagliptin

Sitagliptin,100mg once daily, orally, for 6 months

DRUG

Acarbose

Acarbose,100mg three times daily, orally, for 6 months

Locations (1)

Fudan University affiliated Huadong Hospital

Shanghai, Shanghai Municipality, China